OBJECTIVES: Hypertension is common among patients with dyslipidemia but is often poorly treated. The objective of this analysis was to evaluate how a decision aid, used by primary care physicians to improve lipid therapy, impacted on the treatment of hypertension.
INTRODUCTION
There is little debate that the treatment of hypertension can reduce the morbidity and mortality associated with cardiovascular disease [1] [2] [3] [4] [5] . Despite the consensus and mounting clinical evidence supporting treatment, many patients do not achieve recommended blood pressure targets [1] [2] [3] [4] [5] . Reasons for this are many including inadequate treatment by physicians and suboptimal patient adherence to prescribed therapy [6] [7] [8] [9] [10] [11] . The resulting treatment gap between prevention guidelines and actual clinical practice is now recognized as one of the major challenges facing health care providers in their efforts to prevent coronary disease 12 . A survey of American physicians by Mosca et al. 13 demonstrated that most physicians do not believe they are effective in helping their patients prevent cardiovascular disease. The study identified that the physician's perception of coronary risk for the individual patient was the primary factor associated with prescribing treatment. The authors concluded that educational efforts to assist physicians in coronary risk assessment might increase awareness and adoption of CVD prevention guidelines. These recommendations are consistent with the 2002 American Heart Association guidelines for the primary prevention of coronary disease and stroke 14 . These guidelines recommend that one approach to reducing the treatment gap is to forge a The study was funded by Pfizer Canada. The study design was conceived by the principal investigator and the protocol was reviewed and modified by an independent steering committee (see appendices). The sponsor participated in discussions regarding study design and protocol development and provided logistical support during the trial. The investigators were responsible for data collection, data analysis, and preparation of the manuscript independently of the funding source. The sponsor was permitted to review the manuscript, but all final decisions regarding content remained the responsibility of the principal investigator. Dr. Grover, Dr. Lowensteyn, Mr. Kaouache, Mr. Coupal, and Ms. Marchand have received research grants from Pfizer, Sanofii Aventis, and AstraZeneca. Dr. Grover has received speaker honoraria from Pfizer, Sanofi Aventis, and Orynx. In addition, Dr. Grover has either been a consultant or participated on an advisory board for AstraZeneca, Sanofi Aventis, Pfizer and Merck.
physician -patient partnership by assessing the individual patient's coronary risk and communicating this risk when developing a plan of action with the patient.
The CHECK-UP study was a randomized clinical trial to evaluate the effectiveness of a clinical decision aid to improve the treatment of dyslipidemia and reduce the risk of coronary disease among Canadian patients seen in primary care physicians' offices 15 . Individuals with dyslipidemia were randomly assigned to receive usual care or a personalized risk profile in which the future risk of cardiovascular events and potential benefits of modifying specific risk factors were calculated. As anticipated, a substantial portion of patients enrolled in the study had hypertension, both treated and untreated. We, therefore, evaluated the spill-over effect of the risk profile on the treatment of hypertension.
METHODS

Study Design
The CHECK-UP study has previously been described in detail 15 . 16 . At screening, subjects provided written informed consent and had a complete medical evaluation including a full lipid profile. Subjects were eligible for the study if they met the following criteria:
1. Their risk level was considered very high (had cardiovascular disease, or diabetes present, or a calculated 10-year coronary risk greater than 30%) and their LDL-cholesterol (LDL-C) was equal to or greater than 2.5 mmol/L or their total cholesterol/HDL (TC/HDL) ratio was equal to or greater than 4. 2. Their risk level was high (calculated 10-year risk of 21-30%) and their LDL-C was equal to or greater than 3.0 mmol/L or their TC/HDL ratio was equal to or greater than 5. 3. Their risk level was moderate (calculated 10-year risk of 10-20%) and their LDL-C was equal to or greater than 4.0 mmol/L or their TC/HDL ratio was equal to or greater than 6.
The Coronary Risk Profile
The coronary risk profile is a one-page computer printout that displays a subject's probability of developing coronary disease 18, 19 . For instance, a 50-year-old with a life expectancy of 25 more years (versus 30 years for the average Canadian) would be assigned a cardiovascular age of 55. Once the study was completed, this risk profile became freely available on the McGill Cardiovascular Health Improvement Program website at www.chiprehab.com.
All risk profiles were completed at the study coordinating center and mailed to physicians prior the next patient visit. At entry into the study, subjects randomized into the risk profile group were shown their absolute coronary risk. The relative risk was graphically summarized by comparing this risk to a representative sample of Canadians of the same age and sex using data from the Canada Heart Health Survey 20 . Finally, a copy of the profile was given to the patient to take home. Each subsequent profile compared the patient's current coronary risk with all profiles obtained at previous visits so that patients could follow their response to therapy.
Study Visits
The baseline visit occurred 2-4 weeks following screening, and treatment was initiated with the choice of statin and starting dose left to the investigator. Follow-up visits occurred at 3, 6, 9, and 12 months with a re-evaluation of lipids and safety parameters 2 to 4 weeks prior to each visit. Blood pressure was measured at each visit and physicians were free to initiate or modify antihypertensive medications as they felt appropriate. Although change in blood pressure was not the primary focus of the study, it was measured at each visit as per study protocol using the routine procedures developed in each physician's practice. At each visit, investigators discussed the risk profile with profile subjects, while usual care subjects received routine care as practiced by their physician. To replicate the usual barriers to adherence, all medication was purchased at a pharmacy chosen by the patient. Drug costs were borne by patients using private insurance, public drug plans, or out-ofpocket.
The analyses herein focus primarily on those individuals whose blood pressure was above currently recommended targets. In Canada, hypertension guidelines recommend that blood pressure above 130/80 should be treated in patients with diabetes and the treatment threshold of 140/90 is recommended for all other adults. During the study, the 2001, 2003 Canadian guidelines and the JNC VI American guidelines were in effect 2, 4 . Extrapolating from these three documents, we defined undiagnosed hypertension eligible for treatment as a blood pressure above target on at least three consecutive occasions during the six study visits over one year. Treated hypertension requiring additional therapy was defined as blood pressure above target on two or more consecutive visits.
Data Analysis
Hypertension treatment rates were compared among patients not at blood pressure targets who received a risk profile vs. usual care. There remained the possibility that betweenphysician differences could have an effect on treatment decisions 21 . Accordingly, a random effects logistic regression model was used to estimate the effect of the intervention compared to the control group after adjustment for betweenphysician variability 22 . Patient inclusion and randomization in this trial was based only on the presence of treatable dyslipidemia. We therefore also adjusted for potential confounders that might be associated with treatment including the average systolic and diastolic blood pressure levels prior to patients requiring treatment and the presence of diabetes or cardiovascular disease.
The primary clinical trial results demonstrated that the most important feature of the risk profile was showing subjects their cardiovascular age. A larger "age gap" (difference between cardiovascular age -chronologic age) was positively associated with reaching lipid targets 15 . We therefore completed similar analyses on the hypertensive patients and compared the blood pressure thresholds associated with intensifying treatment (increasing treatment for those already treated or starting treatment among previously untreated patients).
RESULTS
Blood Pressure Above Target
Among 3,053 patients with dyslipidemia, 2,631 completed the full 12-month follow-up, including 1,352 (51%) who did not have previously diagnosed hypertension, and 1,279 (49%) who had diagnosed hypertension and were on medication at entry into the study. The reasons for 366 individuals dropping out of the study have previously been described in detail 15 . None of these drop-outs were due to issues surrounding hypertension treatment. During 12 months of follow-up, 30% of previously undiagnosed individuals were eligible to start treatment while 69% of diagnosed hypertensive subjects were eligible for additional treatment. In the primary randomized trial, randomization resulted in two very comparable groups 15 . Comparing the patients requiring more intensive anti-hypertension treatment who received the risk profiles versus those assigned usual care, the baseline characteristics were also very similar ( 
Effect of the Decision Aid
Among those patients who required more intensive antihypertensive treatment, 178 of 668 (27%) receiving usual care were appropriately treated compared to 212 of 629 (34%) who received the risk profile ( Table 2 ). The 7% (95% CI 2% -12%) absolute increase in appropriate treatment suggests that 14 patients had to receive a risk profile in order for one additional patient to be appropriately treated. Once treatment was intensified, the drop in blood pressure at the next visit averaged 13 mmHg compared to 5 mmHg among those who were not treated. Similar results were observed for initiating treatment among individuals without previously diagnosed hypertension or increasing treatment among those previously treated. Table 2 also presents the unadjusted effect of the risk profile (OR=1.40, 95% CI 1.11 -1.78) or adjusted for between physician differences (OR=1.42, 95% CI 1.11 -1.83) and potential confounders (OR=1.46, 95% CI 1.12 -1.90). The use of the coronary risk profile remained an independent determinant of starting or adjusting antihypertensive treatment among all patients eligible for more intensive treatment, among those without previously diagnosed hypertension and those with known hypertension. In these analyses, the coefficients for each investigator was the random effects factor, and we adjusted for the average systolic and diastolic blood pressure levels prior to patients requiring treatment according to guidelines. The presence of diagnosed cardiovascular disease or diabetes was also forced into the model to adjust for the different treatment strategies associated with these conditions.
To better understand how the risk profile results influenced treatment decisions, we compared the thresholds for intensifying blood pressure therapy among individuals in the risk profile and usual care groups. Compared to the usual care group, blood pressure was only slightly lower in the risk profile group (−1.1 mm) just prior to starting treatment (Table 3) . However, the risk profile for individuals with prior CVD did not include an estimate of their cardiovascular age. Also, some individuals without CVD had received a re-assuring profile where their cardiovascular age was less than or equal to their chronologic age ("age gap" ≤ 0). The age gap had previously been shown to be an important determinant of how the risk profile results impacted on lipid therapy 15 . Accordingly, similar sub-group analyses were preformed on the hypertension treatment results. Treatment was initiated at a higher threshold (5 mm higher) among risk profile patients who were not provided with their cardiovascular age due to the presence of prior CVD. Similarly, there was virtually no difference in the systolic blood pressure treatment threshold between the usual care and risk profile patients (0.4 mm lower) when the age gap was favourable (≤ 0). However, lower blood pressure treatment thresholds were observed when the age gap was >0 (3.2 mm lower). Results among those with a positive age gap were also stratified by the presence of diagnosed diabetes to control for the different treatment goals and one still observed a more pronounced effect among those with diabetes (3.4 mm lower) and those without (3.1 mm lower). Similar trends were observed for diastolic blood pressure. These analyses suggest the use of the risk profile, when the age gap was >0, may have lowered the threshold for intensifying treatment. However, the confidence intervals surrounding the observed differences were wide.
CONCLUSIONS
This secondary analysis of the CHECK-UP study demonstrates that using a coronary risk profile to improve the treatment of dyslipidemia may also have a positive spill-over effect on the management of hypertension. Compared to patients randomized to usual care, patients who were shown their risk profiles were more likely to receive appropriate anti-hypertensive treatment. The previously published, primary results of the study demonstrated a significant "dose response" effect where the impact of the risk profile was greatest among those individuals with the largest "age gap" (difference between their chronologic age and the calculated cardiovascular age) 15 . Although the number of observations was much smaller when anti-hypertensive therapy was examined, the spill-over effect of the profile also appeared to be restricted to those high risk individuals with an age gap >0.
The frequency of poor control in the CHECK-UP study was similar to that reported in other surveys [6] [7] [8] [9] [10] [11] . This was despite the fact that the patients who were evaluated were enrolled in a coronary risk reduction trial albeit one where the primary focus was blood lipid therapy. For instance, among those with treated hypertension, 69% were above target on at least two consecutive visits. A two-year review of blood pressure management among hypertensive men followed in Veteran Affairs sites in New England between 1990-1995 found that during 5,682 clinic visits, hypertension was not well controlled (<140/ 90) 73% of the time 7 . Clearly there remained substantial room for improvement in both patient cohorts. The impact of the risk profile was consistent with a similar randomized trial by Hall et al. evaluating the usefulness of attaching a patient's New Zealand coronary risk score to their charts 23 . Among 323 patients with type 2 diabetes, the overall Age gap is defined as the difference between the patient's "cardiovascular age" and their chronologic age (see Methods for more details). Cardiovascular age was not provided to those patients with previously diagnosed CVD . The potential weaknesses of this study must be recognized. Both physicians and patients were focusing primarily on the treatment of dyslipidemia to reduce coronary risk in a clinical trial. It is therefore not clear to what extent these results reflect current treatment patterns observed outside of a research study. In the absence of long-term follow-up data, it remains unclear whether more intensive hypertension treatment eventually resulted in better blood pressure control. On the other hand the study has a number of strengths. The generalizability of the findings was enhanced given that data were collected longitudinally from a broad sample of primary care practice settings across the country. The cost of lipid and blood pressure medication and the effort to obtain it also reflected patient care as currently practiced under a national health care plan. As the control of hypertension was not the primary focus of this study, the treatment patterns observed among patients were not driven by a study protocol, but rather by usual clinical practice. Accordingly the spill-over effect of the risk profile beyond the primary lipid endpoints could be assessed.
In conclusion, providing patients and their physicians with a coronary risk profile increased the likelihood of appropriately treating hypertension. This suggests that global risk assessment may help physicians and patients to look beyond a single risk factor. Cardiovascular risk assessment decision aids should be further evaluated in a randomized trial of hypertension therapy. study design was conceived by the principal investigator and the protocol was reviewed and modified by an independent steering committee (see appendices). The sponsor participated in discussions regarding study design and protocol development and provided logistical support during the trial. The investigators were responsible for data collection, data analysis, and preparation of the manuscript independently of the funding source. The sponsor was permitted to review the manuscript but all final decisions regarding content remained the responsibility of the principal investigator.
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